What 4 Analyst Ratings Have To Say About Bluebird Bio
What 4 Analyst Ratings Have To Say About Bluebird Bio
關於bluebird bio有4個分析師評級，以下是他們的評價。
In examining recent analyst actions, we gain...4 analysts have expressed a variety of opinions on bluebird bio (NASDAQ:BLUE) over the past quarter, offering a diverse set of opinions from bullish to bearish.
過去一季度，4位分析師對bluebird bio（納斯達克:BLUE）發表了各種各樣的意見，從看好到看淡不一。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
總結他們最近的評估，下表展示了過去30天內不斷變化的情緒，並將其與之前的幾個月進行了比較。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $4.25, a high estimate of $6.00, and a low estimate of $3.00. A decline of 26.09% from the prior average price target is evident in the current average.
經過分析師的分析，12個月的目標股價給出了洞察力，平均目標價爲$4.25，高估值爲$6.00，低估值爲$3.00。與先前的平均價格目標相比，當前平均目標價下降了26.09%。
Exploring Analyst Ratings: An In-Depth Overview
分析師評級:深入了解
In examining recent analyst actions, we gain...
通過檢查最近的...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。